MedTrace Logo

EPA Supplementation on Vascular Inflammation, and Gene Expression of PON2 in Patients With Type II Diabetes Mellitus

NCT03258840 · Status: COMPLETED · Phase: NA · Type: INTERVENTIONAL · Enrollment: 36

Last updated 2017-08-23

No results posted yet for this study

Summary

The aim of this study is to determining of the effects of Eicosapentaenoic acid (EPA) supplementation on serum activities of Paraoxonase-1 and Homocystein thiolactonase, and serum levels of some indicators of vascular inflammation, and the gene expression of PON2 in the peripheral blood mononuclear cell (PBMC) in the patients with type II diabetes mellitus.

Conditions

  • Diabetes Mellitus Type II

Interventions

DIETARY_SUPPLEMENT

EPA Supplement

EPA supplement, 4 × 500 mg softgel daily (2 g per day), 2 times a day, for 8 weeks.

DIETARY_SUPPLEMENT

EPA Placebo

EPA- placebo softgel (Containing 2 g edible paraffin oil), 4 × 500 mg softgel daily, 2 times a day, for 8 weeks.

Sponsors & Collaborators

  • Tehran University of Medical Sciences

    lead OTHER

Principal Investigators

  • Mohammad Hassan Golzari, Ph.D · Department of Nutrition & Biochemistry, School of Public Health, Tehran University of Medical Sciences (TUMS)

  • Mahmoud Djallali, Ph.D · Department of Nutrition & Biochemistry, School of Public Health, Tehran University of Medical Sciences (TUMS)

  • Saeed Hosseini, MD,Ph.D · Department of Nutrition & Biochemistry, School of Public Health, Tehran University of Medical Sciences (TUMS)

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
TRIPLE
Model
PARALLEL

Eligibility

Min Age
35 Years
Max Age
50 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2013-01-31
Primary Completion
2013-04-30
Completion
2014-08-31

Countries

  • Iran

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT03258840 on ClinicalTrials.gov